Peer-influenced content. Sources you trust. No registration required. This is HCN.
Pharmacy Times
“We try to deescalate pharmacotherapy as soon as we can in children. How’s this going to affect puberty? How’s it going to affect growth? We don’t have those long-term data.”
Clinical Pharmacology December 11th 2025
Psych Congress Network
Although not remarkably high, a 2.8% development of psychotic symptoms represents a nonnegligible figure and lends further meta-analytic support to the 2007 FDA change in the drug label for stimulants.
Psychiatry October 9th 2025
Psychiatry Advisor
68% of participants in the amitriptyline group reported worsening sleep following discontinuation, with only 12% describing this as temporary.
Neurology September 30th 2025
GoodRx for Healthcare Professionals
Up to 45% of people in the US experience fatigue, making medication-induced drowsiness a significant clinical consideration when prescribing commonly used drug classes.
Clinical Pharmacology April 29th 2025